CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS
https://doi.org/10.20996/1819-6446-2008-4-4-76-79
Abstract
Cardiovascular event risk reduction with medicines is discussed in the article. The role of randomized controlled trials is emphasized for estimation of therapy effects.
About the Author
S. Y. Martsevich
State Research Center of Preventive Medicine of Rosmedtechnology, Petroverigsky per. 10, Moscow, 101990 Russia
Russian Federation
Chair of Evidence Based Medicine of Moscow Medical Academy named after M.I. Setchenov
Russian Federation
Chair of Evidence Based Medicine of Moscow Medical Academy named after M.I. Setchenov
References
1. Veterans Administration Co-operative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.
2. Yusuf S., Peto R., Lewis J. et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
3. Есht D.S., Liebeson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Supression Trial. N Engl J Med 1991;324(12):781-8.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53.
5. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782–8.
6. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058- 68.
7. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59.
8. Wright J.T. Jr, Dunn J.K., Cutler J.A. et al. for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293(13):1595–608.
9. Dahlf B., Sever P.S., Poulter N.R. et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
10. Wald N., Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-25.
11. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.
12. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28(19):2375-414.
13. Марцевич С.Ю. Проблема лечения статинами в России: помогут ли дженерики? Рационал Фармакотер Кардиол 2006;(2):57-60.
14. Якусевич В.В. Качественное лекарственное средство: каким оно должно быть. Рационал Фармакотер Кардиол 2006;(4):41-6.
Review
For citations:
Martsevich S.Y. CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS. Rational Pharmacotherapy in Cardiology. 2008;4(4):76-79. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-4-76-79
Views:
619
Email this article 